



Hybrigenics appoints Dr. Alain Munoz to its Board of Directors

Dr. Alain Munoz brings over 20 years experience of senior management in the pharmaceutical industry and of Board contribution to biotechnology companies

Paris, 05 October 2011 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, announces today the appointment of Dr. Alain Munoz to its Board as a non-executive independent Director. Dr. Munoz replaces Dr. Bernhard Ehmer, President of ImClone Systems, and will chair the Clinical Advisory board.

Dr. Munoz, cardiologist and anaesthesiologist by training, has over 20 years experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president (VP) and the French pharmaceutical company Fournier as VP of R&D and Business Development, subsequently becoming Senior VP of the Pharmaceutical Division. Under his leadership, numerous drug product registrations were obtained world-wide, generating significant sales (Adenocard[®], Plavix[®], Lipanthyl[®]/Tricor[™], Esclim[®],...). He has an in-depth knowledge of the US and Japanese markets, and has concluded several major licensing deals with world-class partners in the industry. He currently acts as an entrepreneur developing his own projects and an adviser to investors. He is a board member of several biotechnology companies (NYSE Euronext: Vivalis SA, **VLS**; Novagali Pharma SA, **NOVA**. Nasdaq OMX: Zealand Pharma A/S, **ZEAL**).

"I'm delighted to welcome Alain Munoz to the board of Hybrigenics. Alain brings as well scientific and clinical know how as competence in the management of a public French company, thereby complementing the existing competences of the company's board," said Daan Ellens, Chairman of Hybrigenics' Board of Directors. *"I'd like to warmly thank Bernhard Ehmer who has accompanied Hybrigenics' clinical development from scratch in 2006 until the successful completion of Phase IIa of inecalcitol in castrate-resistant prostate cancer this year,"* added Remi Delansorne, Hybrigenics' CEO.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases. Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist, for the first-line treatment of metastatic hormone-refractory prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapy treatment for this indication. Inecalcitol is also being developed to treat severe psoriasis by oral administration. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

HYBRIGENICS

Press Release

Hybrigenics Services SAS is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

* * *

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurer

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr